To disrupt these interactions, we designed novel decoy peptides that potentially competes with both HDAC3 and NME2, effectively inhibiting PIWIL2-driven tumor activity in Huh7, HepG2, SNU449, and SNU398 HCC cell lines. Here, NME2 is linked to neoplasm.